Samumed is developing drugs for multiple degenerative diseases, including osteoarthritis, alopecia (baldness), and degenerative disc disease. While these therapies differ from each other, they all focus on restoring the Wnt signaling pathway.
The Wnt pathway is fundamental in stem cell differentiation. It allows for ordinary tissue repair and upkeep, and it provides for wound healing and recovery from injuries. However, like many other pathways, it becomes deregulated with age. By restoring this pathway, Samumed intends to replenish deteriorating tissues with the body’s own cells, staving off age-related diseases.
Samumed has multiple therapies in human clinical trials, two of which have returned positive results from Phase 2 testing. If these therapies succeed in Phase 3 trials and are found to be effective in clinical practice, they will demonstrate the viability of targeting signaling pathways, potentially paving the way for a broad range of similar therapies.
As of May 2nd, 2019 Samumed launched its phase 3 clinical program of lorecivivint (SM04690) for the treatment of knee osteoarthritis (OA), which will consist of pivotal trials studying the effects of lorecivivint on patient-reported outcomes and disease progression. The pivotal program will be referred to as STRIDES (SM04690 Trial Evaluating a Randomized Injection for Determination of Efficacy and Safety).
Yazici, Y., McAlindon, T. E., Gibofsky, A., Lane, N. E., Clauw, D., Jones, M., … & Tambiah, J. (2020). Lorecivivint, a Novel Intraarticular CDC-Like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Deshmukh, V., Hu, H., Barroga, C., Bossard, C., Kc, S., Dellamary, L., … & Seo, T. (2018). A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease-modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis and cartilage, 26(1), 18-27.
Yazici, Y., McAlindon, T. E., Fleischmann, R., Gibofsky, A., Lane, N. E., Kivitz, A. J., … & Tambiah, J. R. S. (2017). A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis and cartilage, 25(10), 1598-1606.